Coronary artery diseaseEffect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction
Section snippets
Study medication, design, and patients
The study medication consisted of 300-mg capsules of XZK, each containing the combination of lovastatin, also termed monoclonin K (2.5 to 3.2 mg/capsule); a small quantity of lovastatin hydroxyl acid; as well as ergosterol and some other components.
The study protocol was approved by the data and safety monitoring and regional ethics committees of each study site, and informed consent forms were signed by all enrolled patients before study initiation. This randomized, double-blind,
Results
This trial was carried out from May 1996 to December 2003 in 65 hospitals in China, led by the Cardiovascular Institute and Fuwai Hospital at the Chinese Academy of Medical Sciences. Patients (3,986 men, 884 women) were randomly assigned at a ratio of 1:1 into the XZK (n = 2,429) and placebo (n = 2,441) groups. The study plan was to enroll 4,700 patients with 2 interim analyses as prespecified and to discontinue the study upon detection of a significant difference for the primary end point
Discussion
Most large clinical trials with statin therapy examined the impact of about a 25% to 40% fall in LDL cholesterol on the occurrence of CV events and mortality. This relation appears to be greater in patients with rather high levels of LDL cholesterol. The first placebo-controlled multicenter trial with a statin showed a significant decrease in both all-cause mortality and CV events in simvastatin-treated patients with increased serum cholesterol.9 However, because patients with coronary
References (14)
- et al.
Multiple clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine
Curr Ther Res
(1997) - et al.
Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease
Atherosclerosis
(2003) - et al.
Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina
Clin Chim Acta
(2005) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial
Lancet
(2003) - et al.
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
Am J Clin Nutr
(1999) - et al.
Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease
Clin Chem
(2003) - et al.
Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
Circulation
(2004)
Cited by (305)
A historical, evidence-based, and narrative review on commonly used dietary supplements in lipid-lowering
2024, Journal of Lipid ResearchThe current trend and challenges of developing red yeast rice-based food supplements for hypercholesterolemia
2023, Journal of Future FoodsCalcium carbonate nanoparticles tumor delivery for combined chemo-photodynamic therapy: Comparison of local and systemic administration
2023, Journal of Controlled ReleaseLDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals
2023, Nutrition, Metabolism and Cardiovascular Diseases
Members of the Chinese Coronary Secondary Prevention Study Group are listed in the Appendix.
This study was supported by the Chinese National Scientific and Technological Projects, Peoples Republic of China, and sponsored by WPL Peking University Biotech Co. Ltd (WPU), Beijing, Peoples Republic of China.